A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach blockbuster land ahead of schedule. | A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach blockbuster land ahead of schedule.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Incyte has reached a settlement with the Centers for Medicare & Medicaid Services (CMS) regarding rebate criteria for its eczema…
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of…
It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug…
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…
